History of LTT Bio-Pharma

1980~

Apr. 1988 LTT Research Institute was established for the purpose of support of research and development of DDS-related technologies.
Jun. 1988 Limethason®, a DDS product developed by LTT, was marketed by Mitsubishi Tanabe Pharma Corp. (former Green Cross Corp.).
July. 1988 Haloart®, a DDS product developed by LTT, was marketed by Taiho Pharmaceutical Co., Ltd.
Oct. 1988 Palux Injection®, a DDS product developed by LTT, was marketed by Taisho Pharmaceutical Co., Ltd.
Nov. 1988 Liple Injection®, a DDS product developed by LTT, was marketed by Mitsubishi Tanalo Pharma Corp. A contract research agreement was concluded with St. Marianna University.
Oct. 1990 Institute of Medical Science St. Marianna Univ. School of Medicine was established.
Jun. 1992 Ropion Injection®, a DDS product developed by LTT, was marketed by Kaken Pharmaceutical Co., Ltd.
Mar. 1995 Beijing Tide Pharmaceutical Co., Ltd. was established jointly with China-Japan Friendship Hospital, Beijing, China. Manufacturing of Lipo-PGE1 product was started in China with the technical support from Taisho Pharmaceutical Co., Ltd.
Sep. 1998 Farnezone and Farnerate were marketed by Taiho Pharmaceutical Co., Ltd. and Dainippon Sumitomo Pharmaceutical Co., Ltd., respectively.

2000~

Nov. 2001 The head office was moved to Atago, Minato-ku, Tokyo.
Jan. 2003 LTT Bio-Pharma was founded by corporate separation from LTT Research Institute to transfer the pharmaceutical business.
Nov. 2004 LTT Bio-Pharma was listed on TSE Mothers.
Jun. 2005 Perfect Lift AA, a DDS product developed by LTT, was marketed by Rohto Pharmaceutical Co., Ltd.
Nov. 2006 An Early Phase Ⅱ clinical study of PC-SOD has been completed in Japan.
This study showed that PC-SOD was effective for ulcerative colitis.
May. 2008 Dr. Yutaka Mizushima passed away.
Jun. 2008 An Early Phase Ⅱ clinical study of PC-SOD has been completed in Japan.
This study showed that PC-SOD was effective for idiopathic intersttial pheumonia.
Feb. 2009 The head office was moved to Kaigan,Minato-ku,Tokyo.
Feb. 2009 LTT Bio Pharma Transferred Stocks of Sole Corporation.
Deviate from consolidated companies.
Apr. 2009 Capital and business alliance agreement was concluded with Beijing Tide Pharmaceutical Co., Ltd.
Aug. 2009 PC-SOD NE was adopted at NEDO(Government-subsidized projects)
Sep. 2009 LTT-Bio Pharma had an exclusive license agreement (AS-013) with Beijing Tide Pharma at China.
Jan. 2010 LTT Bio Pharma made a collaborative research agreement(Stealth Type Nano-Particle Formulation) with Asahi Kasei Pharma corporation.
It started basic research.
Jul. 2010 Stealth Type Nano-Particle Formulation was adopted at NEDO(Government- subsidized projects)
Sep. 2010 PhaseI study of PC-SOD NE was started.
Nov. 2010 LTT-Bio Pharma had an exclusive license agreement with Beijing Tide Pharma on Stealth Type Nano-Particle Formulation.
Dec. 2010 We started Repeated-dose study of PC-SOD NE(PhaseI study) on healthy volunteer.
Jul. 2011 LTT-Bio Pharma had an exclusive license agreement with Chon Kun Dang Pharma Corp.(CKD) on PC-SOD NE.
Aug. 2011 LTT Bio Pharma’s stocks was delisting. (Aug 9. 2011)
Feb. 2012 Reduced the capital in a hundred million yen. (Feb. 10. 2012)
Investigational New Drug (IND) application of Phase II clinical study for PC-SOD NE.
Jul. 2012 Phase II global clinical trial (Japan and Korea) of PC-SOD NE was started.
Sep. 2014 Phase II global clinical trial of PC-SOD NE has been completed.
Oct. 2015 LT-4004 license contract was concluded with Ajinomoto Pharma Co., Ltd.
Apr. 2016 Established laboratory in St.Marianna University.
May. 2016 Phase II clinical trial of LT-4002 has been started.